Still's disease
RecruitingStudy of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis
- Disease:Still's disease
- Substances:Apremilast
Austria- Participants:0–17 years
- Substances:Apremilast
- Sponsor:Amgen Inc.
Rare diseases
Investigational molecules
Locations
Back to Austria3 clinical trials in Bregenz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.
Austria
Austria
AustriaThe busiest research cities in the country
What the registry says about research in the country
Research focusing on Juvenile Idiopathic Arthritis (JIA), investigating innovative treatment approaches for young patients aged 1-17 years. These clinical trials aim to evaluate new therapeutic options for managing childhood arthritis.
Studies are evaluating the effectiveness of baricitinib as a potential treatment option, with particular attention to safety profiles in pediatric populations.
Tell us about your condition – we search every trial in Europe and connect you with the right site.